28263809|t|Supercritical processed starch nanosponge as a carrier for enhancement of dissolution and pharmacological efficacy of fenofibrate
28263809|a|In current study, supercritical processed starch nanosponge (SSNS) used as a carrier for poorly water soluble drug (fenofibrate) to enhance its in-vitro and in-vivo performance. SSNS was prepared by using sol- gel method and effective supercritical drying technique. Fenofibrate was loaded into the SSNS by using solvent immersion method with selected and optimized organic solvent. BET surface area of SSNS was evaluated by nitrogen adsorption/desorption analysis. SSNS and drug loaded SSNS were characterized by DSC, XRPD, FTIR, SEM, Contact angle study and evaluated for in-vitro, in-vivo studies. The results revealed that the formed SSNS material has high surface area (180m2/gm) with pore size (40 nm to 200nm). The DSC and XRPD study revealed the amorphization of drug within a SSNS. SEM study showed the continuous porous structure with differ nanosized pores of SSNS. Contact angle study showed improvement in aqueous wetting property of drug within a SSNS. In-vitro drug release study showed remarkable dissolution enhancement of SSNS formulation as compared to plain drug. In vivo pharmacodynamic study (hyperlipidaemia model) showed SNSS based formulation significantly improved the bioavailability of drug. Thus SSNS carrier system has good potential to be explored as a delivery system for poorly water soluble drugs.
28263809	24	30	starch	T103	UMLS:C0038179
28263809	31	41	nanosponge	T103	UMLS:C0005479
28263809	47	54	carrier	T103	UMLS:C0013161
28263809	74	85	dissolution	T058	UMLS:C3830465
28263809	118	129	fenofibrate	T103	UMLS:C0033228
28263809	141	146	study	T062	UMLS:C2603343
28263809	172	178	starch	T103	UMLS:C0038179
28263809	179	189	nanosponge	T103	UMLS:C0005479
28263809	191	195	SSNS	T103	UMLS:C0005479
28263809	207	214	carrier	T103	UMLS:C0013161
28263809	226	231	water	T103	UMLS:C0043047
28263809	240	244	drug	T103	UMLS:C0013227
28263809	246	257	fenofibrate	T103	UMLS:C0033228
28263809	287	294	in-vivo	T082	UMLS:C1515655
28263809	308	312	SSNS	T103	UMLS:C0005479
28263809	335	350	sol- gel method	T058	UMLS:C0201683
28263809	365	395	supercritical drying technique	T058	UMLS:C3830390
28263809	397	408	Fenofibrate	T103	UMLS:C0033228
28263809	429	433	SSNS	T103	UMLS:C0005479
28263809	443	467	solvent immersion method	T058	UMLS:C0201683
28263809	496	511	organic solvent	T103	UMLS:C0360100
28263809	533	537	SSNS	T103	UMLS:C0005479
28263809	542	551	evaluated	T058	UMLS:C0220825
28263809	555	594	nitrogen adsorption/desorption analysis	T058	UMLS:C0022885
28263809	596	600	SSNS	T103	UMLS:C0005479
28263809	605	609	drug	T103	UMLS:C0013227
28263809	617	621	SSNS	T103	UMLS:C0005479
28263809	644	647	DSC	T058	UMLS:C0006780
28263809	649	653	XRPD	T058	UMLS:C1135961
28263809	655	659	FTIR	T062	UMLS:C0206055
28263809	661	664	SEM	T058	UMLS:C0026020
28263809	680	685	study	T062	UMLS:C2603343
28263809	690	699	evaluated	T058	UMLS:C0220825
28263809	714	721	in-vivo	T082	UMLS:C1515655
28263809	768	772	SSNS	T103	UMLS:C0005479
28263809	852	855	DSC	T058	UMLS:C0006780
28263809	860	864	XRPD	T058	UMLS:C1135961
28263809	865	870	study	T062	UMLS:C2603343
28263809	901	905	drug	T103	UMLS:C0013227
28263809	915	919	SSNS	T103	UMLS:C0005479
28263809	921	924	SEM	T058	UMLS:C0026020
28263809	925	930	study	T062	UMLS:C2603343
28263809	953	969	porous structure	T082	UMLS:C0678594
28263809	982	997	nanosized pores	T082	UMLS:C1881977
28263809	1001	1005	SSNS	T103	UMLS:C0005479
28263809	1021	1026	study	T062	UMLS:C2603343
28263809	1077	1081	drug	T103	UMLS:C0013227
28263809	1091	1095	SSNS	T103	UMLS:C0005479
28263809	1119	1124	study	T062	UMLS:C2603343
28263809	1143	1154	dissolution	T058	UMLS:C3830465
28263809	1170	1174	SSNS	T103	UMLS:C0005479
28263809	1175	1186	formulation	T062	UMLS:C0524527
28263809	1208	1212	drug	T103	UMLS:C0013227
28263809	1214	1221	In vivo	T082	UMLS:C1515655
28263809	1222	1243	pharmacodynamic study	T062	UMLS:C1709518
28263809	1245	1260	hyperlipidaemia	T038	UMLS:C0020473
28263809	1275	1279	SNSS	T103	UMLS:C0005479
28263809	1286	1297	formulation	T062	UMLS:C0524527
28263809	1312	1320	improved	T033	UMLS:C0184511
28263809	1344	1348	drug	T103	UMLS:C0013227
28263809	1355	1359	SSNS	T103	UMLS:C0005479
28263809	1360	1367	carrier	T103	UMLS:C0013161
28263809	1414	1429	delivery system	T074	UMLS:C0085104
28263809	1441	1446	water	T103	UMLS:C0043047
28263809	1455	1460	drugs	T103	UMLS:C0013227